AZD 9567

Drug Profile

AZD 9567

Alternative Names: AZD9567; AZD9567-monohydrate

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Respiratory tract disorders

Most Recent Events

  • 11 Sep 2017 AstraZeneca completes a phase I trial in Rheumatoid arthritis (In volunteers) in Germany and United Kingdom (PO) (NCT02760316)
  • 25 Aug 2017 Phase-II clinical trials in Rheumatoid arthritis in Denmark (PO) (EudraCT2017-000838-64)
  • 06 Jul 2017 Phase-I clinical trials in Respiratory tract disorders (PO) in United Kingdom (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top